`___________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________________
`
`COALITION FOR AFFORDABLE DRUGS X LLC,
`Petitioner,
`
`v.
`
`ANACOR PHARMACEUTICALS, INC.,
`Patent Owner.
`___________________
`Case No.: IPR2015-01776
`Patent No.: 7,582,621
`__________________
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`Appendix of Exhibits
`Patent No. 7,582,621
`
`EXHIBIT
`
`DESCRIPTION
`
`FILED
`
`Ex. 1004
`
`Ex. 1009
`Ex. 1010
`
`Ex. 1011
`
`Ex. 1012
`Ex. 1013
`
`Ex. 1014
`
`Ex. 1015
`
`Ex. 1016
`
`Ex. 1001 U.S. Patent No. 7,582,621 (“the ’621 Patent”)
`Ex. 1002
`Patent Cooperation Treaty Pub. No. WO 1995/033754 to
`Austin et al. (“Austin”)
`Ex. 1003 U.S. Patent Pub. No. 2002/0165121 to Brehove
`(“Brehove”)
`Patent Cooperation Treaty Pub. No. WO 2003/009689 A1
`to Freeman et al. (“Freeman”)
`Ex. 1005 U.S. Patent No. 6,042,845 to Sun et al. (“Sun”)
`Ex. 1006 Declaration of Stephen Kahl, Ph.D. (“Kahl Decl.”)
`Ex. 1007
`Curriculum Vitae of Stephen B. Kahl, Ph.D.
`Ex. 1008 Declaration of S. Narasimha Murthy, Ph.D. (“Murthy
`Decl.”)
`Curriculum Vitae of S. Narasimha Murthy, Ph.D.
`Prosecution History: U.S. Appl. No. 11/357,687 dated
`February 16, 2006
`Prosecution History: Response To Restriction Requirement
`dated June 6, 2008
`Prosecution History: Office Action dated August 26, 2008
`Prosecution History: Reply to First Office Action dated
`January 23, 2009
`Prosecution History: Notice of Allowance dated April 22,
`2009
`Prosecution History Of Continuation Application:
`Response to Office Action dated May 18, 2009
`Prosecution History: Petition For Reconsideration Of
`Patent Term Adjustment Under 37 C.F.R. 1.705(d) dated
`September 25, 2009
`Prosecution History: Grant of Petition For Reconsideration
`Of Patent Term Adjustment Under 37 C.F.R. 1.705(d)
`dated April 23, 2010
`Prosecution History: Petition To Correct Inventorship
`Under 37 C.F.R. § 1.324 dated May 20, 2010
`Prosecution History: Grant Of Petition To Correct
`Inventorship Under 37 C.F.R. § 1.324 dated July 16, 2013
`Ex. 1020 U.S. Patent No. 2,831,866 to W.A. Freeman et al. (“the
`’866 Patent”)
`
`Ex. 1017
`
`Ex. 1018
`
`Ex. 1019
`
`
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Appendix of Exhibits
`Patent No. 7,582,621
`
`EXHIBIT
`
`DESCRIPTION
`
`FILED
`
`Ex. 1028
`
`Ex. 1021 U.S. Patent No. 3,093,659 to Bell et al. (“Bell”)
`Ex. 1022 U.S. Patent No. 3,297,525 to Grier (“Grier”)
`Ex. 1023 U.S. Patent No. 3,370,957 to Wagner et al (“Wagner”)
`Ex. 1024
`BioborJF® Specification Sheet (2015)
`Ex. 1025
`BioborJF® Material Safety Data Sheet (2004)
`Ex. 1026 U.S. Patent No. 4,202,894 to Pfiffner (“Pfiffner”)
`Ex. 1027 Michael P. Groziak, Boron Therapeutics On The Horizon,
`8 AM. J. OF THERAPEUTICS 321-28 (2001) (“Groziak”)
`Sudaxshina Murdan, Drug Delivery to the Nail Following
`Topical Application, 236 INT’L J. OF PHARM., 1-26 (2002)
`(“Murdan”)
`Ex. 1029 U.S. Patent No. 4,822,822 to Arita et al. (“Arita”)
`Ex. 1030 Declaration of Ryan J. Fletcher (“Fletcher Decl.”)
`Ex. 1031 Kerydin® Prices, available at
`http://www.goodrx.com/kerydin
`Ex. 1032 Q1 Medicare 2015 Kerydin® Price, available at
`http://www.q1medicare.com/PartD-2015MedicarePlan-
`RetailDrugPriceprint.php?stateReg=13MI&ndc=55724011
`121&formulary=00015191&contractId=H2322&planId=00
`8&segmentId=0&zipCountyCode=26115&cplanType=M&
`cletter=K&cmode=state
`Ex. 1033 Declaration of Brent E. Routman in Support of Petitioner’s
`Motion for Admission Pro Hac Vice
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4